0
0
OCD is a psychiatric disorder characterized by persistent intrusive thoughts, known as obsessions, and repetitive behaviors or mental acts, known as compulsions.
Although OCD is known to have a substantial genetic component, researchers have previously identified relatively few genes with strong evidence of involvement.
The new study changes that picture.
Scientists identified 36 high-confidence genes associated with OCD and chronic tic disorders. Four of these genes—CELSR3, CHD8, SCUBE1 and WWC1—had already been identified in earlier research, while the study substantially expanded the list of genes with strong evidence of association.
Four additional genes—BRWD1, CELSR3, QRICH1 and SYNE1—also overlapped with genetic regions previously associated with OCD through genome-wide association studies.
This overlap strengthens evidence that rare genetic mutations and more common genetic variants may converge on some of the same biological mechanisms.
Researchers Used Whole-Exome Sequencing
The researchers used whole-exome sequencing, a technique that examines the protein-coding regions of DNA.
The analysis included individuals diagnosed with OCD, chronic tic disorders or both. Researchers specifically looked for rare and newly occurring mutations that could have a significant impact on biological function.
They found an excess of de novo mutations and rare protein-damaging mutations among affected individuals.
According to the study, these rare mutations were found in approximately 3% to 8% of affected individuals, with an average odds ratio of about 57, indicating that some of the identified variants can have substantial effects on risk.
The researchers emphasize that OCD is not caused by a single gene. Instead, the disorder involves a complex interaction between many genetic factors and other biological and environmental influences.
OCD and Tourette Syndrome Share Genetic Risk
One of the most important findings is the genetic overlap between OCD and chronic tic disorders, including Tourette syndrome.
Both conditions can involve difficulties with controlling repetitive behaviors or urges, although their symptoms are different.
The researchers found that some of the same genetic risk factors are involved in both disorders. Their analysis also showed connections between these genes and other neurodevelopmental conditions.
The findings point toward shared biological pathways involving brain regions and circuits responsible for impulse control, movement and habit formation.
This could eventually help explain why OCD and tic disorders frequently occur together in some individuals.
Genes Are Also Connected to Autism and Schizophrenia
The study revealed another important connection: several of the identified genetic risk factors overlap with genes associated with other psychiatric and neurodevelopmental conditions.
Researchers found biological links involving autism and schizophrenia, suggesting that some psychiatric disorders may share underlying molecular mechanisms.
This does not mean that OCD, autism or schizophrenia are the same condition. Rather, it suggests that certain biological pathways may influence vulnerability across multiple disorders.
Understanding these shared pathways could help scientists investigate whether some therapeutic approaches might eventually be useful across several conditions.
Brain Pathways Could Provide New Treatment Targets
The discovery is particularly important because it could move OCD research closer to treatments that address underlying biological mechanisms.
The researchers’ analyses highlighted genetic activity in several brain regions, including the cerebellum, cortex and striatum, at different stages of development.
The striatum is involved in movement, reward processing and habit formation, while cortical regions play important roles in decision-making and behavioral control.
By understanding how risk genes affect these networks, scientists may be able to identify molecular targets for future drugs.
However, the research does not mean that a new OCD medication is immediately available.
The identified genes represent potential starting points for further laboratory and clinical research. Scientists will still need to determine exactly how individual genetic variants alter brain function and whether those mechanisms can safely be targeted with medicines.
Could Genetic Research Lead to Better OCD Drugs?
Researchers believe the findings could eventually contribute to more precise treatment strategies.
A 2026 review of OCD genetics noted that recent studies have identified multiple genetic pathways involving the brain and immune system. It also highlighted possibilities such as pharmacogenetics and drug repurposing as areas for future clinical translation.
Pharmacogenetics aims to understand how genetic differences influence an individual’s response to medication.
In the future, genetic information could potentially help doctors determine which treatments are more likely to work for particular patients, although such applications are not yet ready for routine clinical use.
Scientists are also investigating whether existing drugs could be repurposed to target biological pathways implicated by genetic studies.
The Research Does Not Yet Provide a Genetic Test for OCD
Despite the excitement surrounding the discovery, experts caution against interpreting the findings as a diagnostic genetic test.
OCD has a highly polygenic architecture, meaning that risk is influenced by many genetic variants rather than a single genetic mutation.
Previous genome-wide research involving more than 53,000 OCD cases and over 2 million controls identified 30 significant genomic loci and estimated that thousands of genetic variants contribute to OCD’s heritable risk.
The latest study adds rare, large-effect genetic variants to that broader picture.
Together, the findings suggest that OCD arises through a complicated combination of common genetic variation, rare mutations and other biological and environmental factors.
Why the Discovery Matters for People With OCD
OCD can be highly disruptive, particularly when symptoms become severe or interfere with work, education, relationships and everyday activities.
Current treatment options can help many people, but not everyone responds adequately, creating an ongoing need for new therapeutic approaches.
The latest genetic discovery could help researchers move beyond simply treating symptoms toward understanding the biological mechanisms that contribute to OCD.
That distinction is important.
Rather than asking only how to reduce compulsions or intrusive thoughts, researchers can increasingly investigate why particular brain circuits become vulnerable to OCD in the first place.
More Research Is Needed Before New Treatments Arrive
The discovery of 36 high-confidence risk genes is an important research milestone, but it is not the final step.
Scientists must now determine how each gene affects biological processes and whether those effects can be modified safely.
Laboratory studies, animal models and eventually human clinical trials will be necessary before any gene-informed treatment can become part of standard medical care.
Researchers also need to expand genetic studies to include more diverse populations. A recent review noted that much of the existing OCD genetic evidence has been based on people of European ancestry, highlighting the need for greater ancestral diversity in future research.
A New Direction for OCD Research
The identification of 36 genes represents a significant expansion of the biological map of OCD and chronic tic disorders.
It also reinforces the idea that psychiatric conditions cannot always be understood through symptoms alone. Genetic and molecular research is increasingly revealing connections between brain circuits, development, neurotransmission and other biological systems.
For OCD research, these findings could provide a new roadmap for identifying treatment targets.
The immediate impact will be scientific rather than clinical. But over time, a clearer understanding of the genes and pathways involved could help researchers develop more targeted therapies and potentially improve treatment for people who do not benefit sufficiently from existing options.
The discovery of 36 genes linked to OCD and chronic tic disorders offers scientists a much clearer picture of the genetic factors contributing to these conditions.
The findings strengthen evidence that OCD shares biological pathways with tic disorders and other neurodevelopmental or psychiatric conditions. They also provide potential targets for future drug development and genetically informed treatments.
For now, however, the discovery should be viewed as a promising research breakthrough rather than an immediate medical solution.
Further studies will be needed to understand how these genes influence the brain and whether they can be safely targeted.
Still, by revealing dozens of previously underappreciated genetic risk factors, scientists have taken an important step toward a future in which OCD treatments could become more biologically targeted and personalized.
